Cardiac Biomarkers Market Overview

The Cardiac Biomarkers Market Predictable at $1.45 billion in 2022, is estimated to increase at a CAGR of 10.35% from $ 13.37 billion in 2023 to $34.45 billion by 2030.

The increasing use of cardiac biomarkers, including myoglobin, troponin I and T, BNP, and myocardial muscle creatine kinase, as a diagnostic tool for cardiovascular disorders is increasing demand. These naturally occurring molecules, such as proteins, hormones, and enzymes, are released into the blood during circulatory diseases, indicating irregularities in the heart system's operation. Healthcare experts are focusing on identifying these specific indicators for critical cardiac disorders like ACS and heart attacks.

People with pre-existing medical disorders, such as diabetes, heart disease, among others, are more susceptible to the novel coronavirus, according to the World Heart Federation, Harvard University study, and other sources. Additionally, COVID-19 individuals with pre-existing cardiac disease are more likely to experience a heart attack or develop congestive heart failure. Myocarditis, a relatively uncommon disease, has been seen in COVID-19 patients admitted to emergency rooms around the world. Furthermore, the National Health Commission (NHC) of China found that 17.0% of COVID-19 patients had coronary heart disease and 35.0% of all patients with the diagnosis had hypertension (based on a sample size of 46,248).

>>>Download Sample Report Now: https://marketreportservice.com/request-sample/cardiac-biomarkers-market-54420 

Cardiac Biomarkers Market Segment Analysis

Troponin testing is becoming a lucrative business due to its advantages in detecting myocardial infarction and congestive heart failure, as well as its fast and accurate diagnosis of cardiovascular illnesses. Cardiac troponins are the best blood test for those suspected of acute myocardial infarction or cardiac heart failure, as they are sensitive and precise biomarkers of myocardial ischemia. The study segment is expected to develop due to the high levels of specificity and efficacy of troponin tests.

The BNP and NT-proBNP segment is expected to rapidly expand due to its use in identifying cardiac disease and stress. New competitors are entering the market, such as LumiraDx Limited, which plans to diversify its portfolio with the CE Mark for its D-Dimer test and NT-proBNP test, expected to be commercially available by the end of 2022.

Market Dynamics

Drivers

The COVID-19 pandemic has led to a surge in cardiovascular disorders, necessitating increased research and development efforts to develop new cardiac biomarkers.

The global burden of cardiovascular diseases (CVDs) is increasing due to factors like smoking, diabetes, obesity, and lifestyle changes. In the US, 1 in 4 deaths are due to CAD, and 1.5 million myocardial infarction cases occur annually. In the UK, 103,000 people get myocardial infarction annually. The rising prevalence of cardiovascular illnesses is expected to be a key factor influencing market growth in the coming period.

Restraints

The lack of specificity in cardiac biomarker analysis necessitates a more sensitive approach, while FDA regulations and technical issues with sample collection and storage pose challenges.

Competitive Landscape of the Cardiac Biomarkers Market

• Abbott Laboratories
• Hoffmann-La Roche Ltd.
• bioMérieux Inc.
• Creative Diagnostics
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Siemens Healthineers

Recent Developments in Cardiac Biomarkers Market

Hoffmann-La Roche Ltd. announced the launch of its five new applications for its prominent key cardiac biomarkers that were in combination with the company’s Elecsys technology. They work efficiently in managing cardiovascular diseases and thus assist clinicians in the diagnosis of heart attacks and managing heart failures.

Siemens AG announced that the company got CE Mark approval for Atellica VTLiPatient-side Immunoassay Analyzer, which is a high-sensitivity troponin I test. This device can detect acute myocardial infarction more effectively.

The sales growth of cardiac biomarkers is being hindered by various factors.

Cardiovascular biomarkers are crucial in epidemiology studies for investigating various stages of human disorders. However, careful handling and storage of these samples are necessary to obtain detailed information. Strong quality control measures are necessary to prevent data loss. Studies rely on archived specimens, which depend on their integrity and collection, process, and storage. Technical issues in sample collection and storage are expected to hinder expansion opportunities in the coming decade

The global demand for cardiac biomarkers is on the rise due to various reasons.

"Increasing Need for Cardiac Biomarkers to Accelerate the Treatment Process"

Heart attack, acute coronary syndrome, heart failure, and myocardial infarction are only a few of the cardiovascular disorders for which cardiac biomarkers are widely employed in the early diagnosis. The WHO (World Health Organisation) reports that many people worldwide suffer from myocardial infarctions or strokes each year.

Patients with coronary heart disease frequently experience acute coronary syndrome. The severity of the problem necessitates the hospitalisation of numerous patients. Therefore, it is anticipated that the rising prevalence of cardiovascular diseases would increase the need for early diagnosis in order to receive prompt treatment, increasing the use of cutting-edge cardiac biomarker testing.

The phrase "Emerging Markets with Increasing Cases of Heart Issues"

India, among emerging markets, is experiencing significant growth potential for cardiac diagnostic product providers due to the increasing prevalence of cardiovascular diseases due to factors like high blood pressure, diabetes, and obesity.

Regional Analysis

The "Presence of Several Prominent Players and Strong Product Portfolio"

In the upcoming ten years, it is expected that the United States will continue to rule North America. Cardiovascular biomarker research is progressing as a result of rising R&D spending on healthcare facilities. Furthermore, the existence of several well-known firms and their robust product portfolios are creating profitable market prospects.

Technologically advanced cardiac biomarkers are expected to significantly grow in China and India over the next decade, driven by the increasing healthcare infrastructure and the growth of these markets.

Segments Covered in the Cardiac Biomarkers Market Report

By Product:

• Creatine Kinase
• Troponins
• Myoglobin
• Natriuretic Peptides
• Ischemia Modified Albumin (IMA)

By Application:

• Myocardial Infarction
• Acute Coronary Syndrome (ACS)
• Congestive Heart Failure
• Atherosclerosis

By Location of Testing:

• Point-of-care Testing
• Laboratory Testing

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Frequently Asked Questions

What is the expected growth rate of the Cardiac Biomarkers market over the next 7 years?

Expanding at a noteworthy CAGR of 10.35%, the global Cardiac Biomarkers market is set to increase from a value of US$ 34.45 billion in 2030.

Who are the major players in the Cardiac Biomarkers market and what is their market share?

Abbott Laboratories, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Randox Laboratories Ltd., Siemens Healthineers, and BioMérieux SA, are prominent players operating and dominating in the market.

Which Region is expected to witness the highest growth in the Cardiac Biomarkers Market?

The Cardiac Biomarkers market is predicted to experience the most significant growth in the United States region over the next seven years.